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Cell-based studies support the existence of two promoters on the
heavy strand of mtDNA: heavy-strand promoter 1 (HSP1) and HSP2.
However, transcription from HSP2 has been reported only once in
a cell-free system, and never when recombinant proteins have been
used. Here, we document transcription from HSP2 using an in vitro
system of defined composition. An oligonucleotide template repre-
senting positions 596–685 of mtDNAwas sufficient to observe tran-
scription by the human mtRNA polymerase (POLRMT) that was
absolutely dependent on mitochondrial transcription factor B2
(TFB2M). POLRMT/TFB2M-dependent transcription was inhibited
by concentrations of mitochondrial transcription factor A (TFAM)
stoichiometric with the transcription template, a condition that acti-
vates transcription from the light-strand promoter (LSP) in vitro.
Domains of TFAM required for LSP activation were also required
for HSP2 repression, whereas other mtDNA binding proteins failed
to alter transcriptional output. Binding sites for TFAM were located
on both sides of the start site of transcription fromHSP2, suggesting
that TFAM binding interferes with POLRMT and/or TFB2M binding.
Consistentwith a competitive bindingmodel for TFAM repression of
HSP2, the impact of TFAM concentration on HSP2 transcription was
diminished by elevating the POLRMT and TFB2M concentrations. In
the context of our previous studies of LSP and HSP1, it is now clear
that three promoters exist in human mtDNA. Each promoter has
a unique requirement for and/or response to the level of TFAM
present, thus implying far greater complexity in the regulation of
mammalian mitochondrial transcription than recognized to date.
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Human mitochondrial DNA (mtDNA) encodes 13 proteinsessential to formation of a functional electron transport
chain and ATP synthase. In addition, mtDNA encodes rRNAs
and tRNAs required for translation of the 13 mRNAs for the
mtDNA-encoded proteins. One strand of mtDNA is referred to
as the heavy strand, and the other strand is referred to as the
light strand. Transcription of the heavy strand produces 2
rRNAs, 12 mRNAs, and 14 tRNAs, whereas transcription of the
light strand produces only 1 mRNA and 8 tRNAs. Given this
genome organization, at least two promoters are needed: a light-
strand promoter (LSP) and a heavy-strand promoter (HSP). The
works by Montoya et al. (1, 2) identified two transcripts from the
heavy strand. They differed both in the site of initiation and the
site of termination (2). One transcript initiated 25 bp upstream
of the phenylalanyl tRNA gene and frequently ended immedi-
ately after the 16S rRNA gene. The other transcript initiated
immediately upstream of the 12S rRNA gene but terminated at
an undefined position after the threonyl tRNA gene, thus pro-
ducing a near genome-length polycistronic RNA. The former
promoter has been termed HSP1; the latter promoter has been
termed HSP2 (Fig. 1A).
Basal transcription initiation on mtDNA was thought to use
three factors regardless of the promoter: mtRNA polymerase
(POLRMT), transcription factor A (TFAM), and transcription
factor B2 (TFB2M). The long-standing paradigm was that TFAM
binds to a site in the promoter upstream of the transcription start
site and recruits a complex POLRMT/TFB2M by an interaction of
the carboxyl-terminal tail of TFAMwith TFB2M (3). However, we
recently showed that basal mitochondrial transcription is not ab-
solutely dependent on TFAM (4). This observation suggested that
the two-component transcription system found in lower eukaryotes
had acquired an additional layer of regulation in mammals that is
mediated by TFAM (4). TFAM is a member of the high mobility
group (HMG) box family of DNA binding, bending and wrapping
proteins (3). For LSP and HSP1, TFAM-mediated activation has
been linked directly to the ability of TFAM to impose a U-turn in
the TFAM-responsive element (TRE) to which it binds (5–7).
The robustness and specificity of transcription from LSP
in vitro encouraged the use of this promoter to study mito-
chondrial transcription in vitro both in cell-free (8) and
recombinant (9–11) systems. Most of these studies showed that
the strength of LSP is substantially greater than HSP1 in vitro
(9), although HSP1 seems to be stronger than LSP in cells (2).
We recently resolved this apparent contradiction by using an
oligonucleotide template that included LSP, HSP1, and the in-
tervening interpromoter region (IPR), a better mimic of the
mtDNA control region (4). In the absence of TFAM, signifi-
cantly more transcription was observed from HSP1 than from
LSP (4). However, concentration of TFAM equivalent to tem-
plate caused full activation of transcription from LSP without
changing the level of transcription from HSP1. When the con-
centration of TFAM exceeded the concentration of the template
by 5- to 10-fold, transcription from LSP was inhibited sub-
stantially, but transcription from HSP1 was still activated sub-
stantially. These observations further strengthened the hypoth-
esis that a TFAM-regulated, two-component transcription
system is operative in human mitochondria.
The least understood promoter is HSP2. The first reports of its
existence were published in the early 1980s (1, 2). However, evi-
dence of its activity using a cell-free system took nearly 25 years to
acquire (12). Recently, however, the work by Litonin et al. (13)
called into question the existence of HSP2 based on the inability to
observe transcription fromHSP2 using recombinant proteins under
conditions in which transcription from LSP is robust. We confirm
herein the existence of HSP2 using a highly purified transcription
system in vitro (14). We find that POLRMT and TFB2M together
are necessary and sufficient for transcription from HSP2 and that
TFAM represses transcription from HSP2 by binding to TREs
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flanking the transcription start site, thus preventing productive
binding of POLRMT and TFB2M. Importantly, the domains of
TFAM required for transcriptional activation of LSP are the same
as those required for transcriptional repression of HSP2. Our in-
ability to identify a single condition that supports maximal tran-
scription from all three promoters in vitro may underpin an
unappreciated mechanism for differential expression of the human
mitochondrial genome in vivo. We discuss the possibility that such
a TFAM-regulated program may permit the energy-producing
demands of the mitochondria to be maintained without a commit-
ment to biogenesis.
Results
Transcription from HSP2 in Vitro.Whether expression of the human
mitochondrial genome requires two or three promoters is fun-
damental to our understanding of mitochondrial biology. We
have shown that POLRMT, TFAM, and TFB2M produced in
bacteria are capable of bona fide initiation of transcription from
LSP and HSP1 using either linearized plasmid or synthetic oli-
gonucleotide templates in vitro (14). We used that system here to
determine if transcription from HSP2 could be observed in vitro.
Two plasmid-derived fragments were evaluated. The first
fragment spanned from position 468 to position 3,325 of mtDNA,
which is referred to as LONG in Fig. 1A. The other spanned from
position 572 to position 3,325 of mtDNA, which is referred to as
SHORT in Fig. 1A. Both constructs omitted mtDNA sequences
from 709 to 3,223 (Fig. 1A). The LONG template contains both
heavy-strand promoters; the SHORT template only contains
HSP2. Assuming the transcription start sites (TSSs) for HSP1
(561) and HSP2 (646) previously reported (12), the HSP1 runoff
transcript should be 301 nt in length, and the runoff transcript
fromHSP2 should be 216 nt in length (Fig. 1A). In the presence of
all three factors, a ladder of transcription products was evident
that complicated interpretation of the experiment when the
LONG template was used (Fig. 1B, lane 2). However, omission of
TFAM revealed two bands of the expected size (Fig. 1B, lane 3).
We have shown previously that transcription from HSP1 can be
TFAM-independent. This experiment, therefore, suggested the
possibility that transcription from HSP2 may also be TFAM-in-
dependent. To determine if the band migrating around 216 nt was
indeed a product of transcription from HSP2, we used the
SHORT template. In the presence of all three components, the
216-nt product was formed; however, a product consistent with
the entire length of the template was also visible (Fig. 1B, lane 4).
When TFAM was omitted, the primary transcription product was
consistent with the product expected fromHSP2 (Fig. 1B, lane 5).
Next, we turned to an oligonucleotide template. The core of
LSP and HSP1 is contained from 50 bp upstream to 40 bp
downstream of the TSS (14). We used a fragment spanning from
position 596 to position 685 (Fig. 1C) (Table S1). Neither
POLRMT alone nor combined with TFAM was sufficient for
anything more than nonspecific transcription (Fig. 1D). Use of
POLRMT and TFB2M was quite robust in production of a run-
off transcript that migrated between the 40- and 50-nt markers
(Fig. 1D). Unexpectedly, addition of TFAM at a concentration
equivalent to POLRMT and TFB2M substantially reduced the
amount of runoff product observed (Fig. 1D). This same con-
dition leads to activation of transcription from LSP when an
oligonucleotide template is used (14). These data confirm the
existence of HSP2 and suggest that TFAM is a potent repressor
of transcription from this promoter.
Position 644 as a Start Site for Transcription from HSP2 in Vitro. The
runoff product of transcription from HSP2 migrates slower than
expected for a 40-nt RNA (Fig. 1D). To show that the runoff
product originated from a site in the vicinity of the expected start
site, we evaluated three additional constructs. We removed 10 bp
upstream of the TSS (Fig. 2A, HSP2-2), and we added 10 bp up-
stream of the TSS (Fig. 2A, HSP2-3). We also extended the tem-
plating region by 10 bp (Fig. 2A, HSP2-4) (Table S1). In all cases,
runoff products in the appropriate size range were observed (Fig.
2B, lane −TFAM), and transcription was still inhibited by the
presence of TFAM (Fig. 2B, lane +TFAM). When the central 24
bp of HSP2 were randomized (Fig. S1A), this template failed to
produce a 40-nt runoff product (Fig. S1B, HSP2-Random). For-
tuitously, a sequence resembling the proposed TSS was present 14
bp upstream that supported some transcription (Fig. S1B, HSP2-
Random). Changing the nucleotide sequence around the TSS of
the plasmid-derived template also abrogated transcription
(Fig. S1C). We conclude that the start site is located in the ex-
pected region.
Attempts to directlymap the 5′ end of the product RNAusing 5′
RACE failed. We were, therefore, forced to use indirect methods
to identify the TSS. Di- and trinucleotide primers capable of hy-
bridizing to the templating bases can be used as primers for RNA
synthesis by POLRMT (11, 14). The TSS proposed in the work by
Martin et al. (12) is 3′-GTT-5′, which corresponds to an RNA 5′
end of 5′-CAA-3′. Therefore, the use of a CA dinucleotide primer
should lead to production of a 40-nt product using the HSP2 oli-
gonucleotide template. To permit this experiment to be inter-
preted, we labeled the primer with 32P. The labeled CA primer
failed to produce a runoff transcript (Fig. S2A, pCpA). Both anAA
dinucleotide primer and an AAA trinucleotide primer produced
runoff products (Fig. S2A, pApA and pApApA). The inability of
the CA dinucleotide to prime runoff transcription and the appar-
ent mobility of the runoff exceeding 40 nt led us to conclude that
Fig. 1. HSP2 transcription in vitro. (A) Schematic of mtDNA promoters: LSP, HSP1 and HSP2, interpromoter region, TRE for LSP and HSP1, and nearby genes.
This region of mtDNA was used to produce LONG and SHORT templates capable of producing the indicated runoff transcripts. (B) Runoff transcription from
the LONG or SHORT templates and indicated factors. All experimental details for this experiment and subsequent experiments are provided in SI Materials
and Methods. M designates size markers. (C) Sequence of DNA oligonucleotide representing HSP2; the proposed TSS is indicated by +1. (D) Runoff tran-
scription from the HSP2-1 template and indicated factors.




















the TSS was at position 644 and/or 643, upstream of the position
observed in the work by Martin et al. (12).
RNA may not migrate at the expected size relative to a marker
because of sequence differences that, for example, prevent
complete denaturation. To produce RNA of the size and se-
quence expected for initiation from position 644, we fused this
sequence to LSP (Fig. S2B, LSP-HSP2 template). The LSP
template produced a 40-nt product (Fig. S2C, lane 2). The LSP-
HSP2 template produced a 42-nt product (Fig. S2C, lane 3), and
this product migrated at the same position as one of the products
observed using the HSP2 template (Fig. S2C, lane 4). We con-
clude that more than one TSS exists for HSP2 in vitro; one TSS is
at position 644. The work by Zollo et al. (15) reached the
same conclusion.
We used a pApApC trinucleotide primer to further document
the specificity of initiation from position 644. As shown in Fig. 2C,
transcription products of specific lengths are predicted when
pApApC is used with specific combinations of nucleotides. Con-
sistent with position 644 as a start site, products of the expected
length were observed (Fig. 2D).When a pApApA primer was used,
a 43-nt product was formed (Fig. 2E, lane 2). A pApCpA primer
yielded a 41-nt product (Fig. 2E, lane 4). Again, the pApApC
primer yielded themost product (Fig. 2E, compare lane 3with lanes
2 and 4). Collectively, these data confirm specificity of initiation
from HSP2, with position 644 serving as the primary TSS in vitro.
The adenylate residue at position 644 of human mtDNA and
adjacent nucleotides are conserved in mouse and bovine species
(Fig. 2F). Interestingly, the POLRMT and TFB2M pair from
mouse failed to produce the 42-nt product using the human
HSP2 template (Fig. 2G). A nonspecific product of template
length (90 nt) was observed (Fig. 2G). Importantly, the combi-
nation of POLRMT, TFB2M, and TFAM from mouse was active
for promoter-specific transcription using a mouse LSP template
(Fig. S3). We conclude that the initiation from HSP2 observed
here is not just a reflection of the presence of a cryptic TSS
capable of being recognized by any POLRMT in vitro.
Repression of HSP2 Transcription by TFAM. TFAM has two well-
documented activities. It serves as a transcriptional activator for
LSP and HSP1 (16, 17) and a packaging protein of the mtDNA
nucleoid (18). TFAM has three functional domains: two HMG
boxes and a carboxyl-terminal domain (CTD) (Fig. 3A). The
CTD seems to be uniquely important for the transcriptional
functions of TFAM (8). Portions of the CTD seem to govern
DNA binding specificity/affinity (5, 19, 20), and portions seem to
govern interactions with proteins (for example, TFB2M) (3).
Therefore, we asked if the CTD was important for transcrip-
tional repression of HSP2 by TFAM. Transcription from HSP2
was evident in the absence of TFAM (Fig. 3B, −TFAM). Again,
transcription from HSP2 was inhibited by the presence of TFAM
(Fig. 3B, +TFAM) but not by the presence of TFAM lacking the
terminal 26-aa residues (Fig. 3B, +TFAM-ΔCT26). Interest-
ingly, the terminal 10-aa residues were not required for re-
pression (Fig. S4A, +TFAM-ΔCT10).
The work by Wong et al. (20) details an extensive biophysical
characterization of TFAM-ΔCT26. The only effects of the de-
letion noted in the work by Wong et al. (20) were related to the
loss of the monomer–dimer equilibrium observed for this protein
and a twofold reduction in its ssDNA binding activity (without
a significant change of its dsDNA binding activity) (20). We used
an EMSA to investigate the DNA binding properties of TFAM
and TFAM-ΔCT26 (Fig. 3C). Four protein–DNA complexes (I–
IV) were formed with both proteins using the HSP2 template as
a probe (Fig. 3C). However, formation and/or stability of
Fig. 2. Specificity of HSP2 transcription in vitro. (A) HSP2 transcription templates designed to assess the specificity of initiation. (B) Runoff transcription from
the templates shown in A by POLRMT-TFB2M in the absence or presence of TFAM. (C) Sequence surrounding HSP2; shown are the expected start sites and
sizes of RNA transcripts when using pApApC, pApApA, or pApCpA trinucleotide primer for initiation with the indicated nucleotide(s). (D) Transcription by
POLRMT-TFB2M from the HSP2-1 template in the presence of pApApC and the indicated nucleotide(s). (E) Runoff transcription from the HSP2-1 template in
the presence of pApApA, pApApC, or pApCpA trinucleotide primer and all four nucleotides. (F) Alignment of human HSP2 with corresponding mouse and
bovine sequences reveals a region of high interspecies differences from −18 to −6. (G) Mouse POLRMT-TFB2M fails to produce a promoter-specific runoff
transcript from human HSP2 indicating specificity of human POLRMT-TFB2M.



























complex I was reduced substantially by deleting the carboxyl-
terminal 26-aa residues of TFAM (Fig. 3C). When a probe
containing the randomized version of the sequence for the LSP
template was used, formation and/or stability of all four com-
plexes were diminished for TFAM (Fig. S4B). We conclude that
formation and/or stability of complex I require sequences in
HSP2 and the TFAM CTD. Therefore, it is possible that the
reduced level of complex I formed on HSP2 by TFAM-ΔCT26
leads to the inability of this derivative to repress transcription
from HSP2. Consistent with this interpretation, formation of
complex I on the LSP template (Fig. S5A) correlates with the
ability of TFAM to activate transcription from LSP (Fig. S5 B
and C). Other mtDNA binding proteins, particularly the ssDNA
binding protein and termination factor, produced no effect on
HSP2 transcription and failed to bind to the HSP2 template
when the proteins were present in the 1–10 nM range (Fig. S6).
Complex I of LSP corresponds to the well-documented TRE
observed by DNase I footprinting (Fig. S5D) (14). Therefore, we
asked if we could identify a TRE in HSP2 by DNase I foot-
printing. We observed two sites of protection. The site most
clearly protected by TFAM was located at a position between
−15 and −10 relative to the TSS (Fig. 3D, region A1). Protection
at sites around +1 and +5 was also evident (Fig. 3D, regions A2
and A3, respectively). Protection was also observed downstream
of the TSS (for example, at +30) (Fig. 3D, region D). Under
these same conditions (2–20 nM TFAM), complexes I and II
were the most abundant complexes formed (Fig. 3C). All of
the protection observed on HSP2 was less pronounced than
the protection observed on LSP (Fig. S5D). Worth noting, the
DNase I accessibility of several regions did not change in this
experiment (Fig. 3D, regions B and C). We conclude that TREs
exist in HSP2 that are located in positions that should be capable
of inhibiting binding by POLRMT-TFB2M.
We reasoned that if the mechanism of repression by TFAM
relates to competition with POLRMT-TFB2M for binding to the
promoter, then TFAM repression should be reduced by increasing
the concentration of POLRMT-TFB2M present in the reaction.
POLRMT-TFB2M at a concentration of 400 nM fully overcame
repression by 10 nM TFAM [Fig. 3E, +TFAM (10 nM)]. However,
this same concentration of POLRMT-TFB2M was insufficient to
overcome 100 nM TFAM [Fig. 3E, +TFAM (100 nM)]. Also con-
sistent with a competitive mechanism was the finding that the in-
hibitory potential of TFAM onHSP2 transcription was antagonized
by the presence of a 28-bpDNAoligonucleotide containing the LSP
TRE (Fig. S7, TFAM-BS). A 28-bpDNAoligo of random sequence
was not as potent of an antagonist, and in fact, it was inhibitory under
conditions in which the TFAM-BS was stimulatory (Fig. S7, com-
pare TFAM-BS with random). We conclude that TFAM represses
transcription from HSP2 by using a classical paradigm for
transcriptional repression in which the repressor binding site
overlaps the polymerase binding site in the promoter (21).
Functional Conservation of Mammalian TFAM. The work by Gaspari
et al. (10) has shown that an interspecies exchange of POLRMT
does not support transcription from LSP, but interspecies ex-
change of TFAM does support transcription from LSP. Our find-
ing that mouse POLRMT-TFB2M does not support transcription
from HSP2 is consistent with the data for LSP (Fig. 2F) (10).
Evaluating the exchangeability of TFAM was of interest to us,
because themost divergent portion of theTFAMCTD is in the last
10-aa residues (Fig. 4A), which are not required for transcriptional
repression (Fig. S4A) or transcriptional activation (Fig. S5E). In-
terestingly, TFAMs from mouse and bovine species were able to
inhibit transcription from HSP2 (Fig. 4B), and these noncognate
TFAMs were able to form complexes I and II on human HSP2 as
efficiently as human TFAM (Fig. 4C). Similar observations were
made with mouse TFAMs on human LSP (Fig. S5). These data
illuminate a role for residues 220–236 of TFAM in the formation
of complexes with TREs of mtDNA, whether these interactions
are activating or repressing. Functionally, these interactions are
likely conserved and exchangeable between mammalian species.
Discussion
Implicit in the elaboration of a genome to include multiple pro-
moters is the existence of regulated gene expression. The multi-
cellular eukaryote, Caenorhabditis elegans, has one of the smallest
mitochondrial genomes known and is thought to use a single
promoter for expression of a single polycistronic RNA. Therefore,
there is likely a biological reason that mammals have expanded
their mitochondrial genomes to include a control region that is
home to at least two promoters: LSP and HSP1 (3). The initial
objective of this study was to determine if we could confirm the
existence of HSP2, a promoter predicted by cell-based studies (1,
2, 12) but disputed by some biochemical studies (13).
All of the experiments reported here are consistent with the
existence of a second heavy-strand promoter (Figs. 1 and 2).
Transcription from HSP2 is strictly dependent on POLRMT and
TFB2M (Fig. 1). Our experiments suggested TSSs at positions 643
and/or 644, with position 644 preferred in our in vitro system (Fig.
2D and Fig. S2). Our observations are consistent with the S1
Fig. 3. Repression of HSP2 transcription by TFAM in vitro. (A) TFAM uses two HMG boxes (Boxes A and B) for DNA binding and CTD for transcriptional ac-
tivation. The activation portion of the CTD is deleted in TFAM-ΔCT26. (B) TFAM-ΔCT26 does not inhibit runoff transcription from the HSP2-1 template by
POLRMT-TFB2M. (C) EMSA of HSP2-1 template over a range of TFAM concentrations shows formation of four complexes (I–IV), with complex I present from 0.5
nM. Formation of complex I is impaired for TFAM-ΔCT26. (D) DNase I footprinting of TFAM-HSP2-1 complexes reveals protection in the regions designated as A1,
A2, A3, and D without protection in regions B and C. A schematic of HSP2-1 is shown on the left, and size markers (M) are on the right. (E) Runoff transcription
from the HSP2-1 template (100 nM) in the absence or presence of 100 or 10 nM TFAM, which are values that are 10-fold higher than or equivalent to the
equilibrium dissociation constant, respectively. In this experiment, product formed at 30 min over the indicated range of POLRMT-TFB2M concentrations.




















mapping and 5′ RACE experiments of HSP2 in vitro transcripts in
the work byZollo et al. (15). However, these start sites do not agree
with the TSS at position 646 inferred from S1 mapping of HSP2
transcripts isolated from cells (12). The reason for this difference is
unclear. One interesting possibility is that start site selection at
HSP2 may be a regulated event (22). For example, mtDNA to-
pology, additional transacting factors, and/or nucleotide pools
could alter the TSS (23–25). If initiation from this promoter is as
variable in vivo as it is in vitro, then it is also possible that some
technical procedural nuance led to loss of 5′-A terminated tran-
scripts or enrichment of the 5′-C terminated transcripts. The use of
multiple start sites fromposition−3 to+3 relative to a primary start
site is well-documented in the nuclear genomes of mammals (26).
The orthologous mouse POLRMT-TFB2M pair was not able to
initiate transcription from human HSP2 (Fig. 2F). Although this
observation suggests that the ability of human POLRMT-TFB2M
to use this promoter is not fortuitous, the factor–promoter in-
compatibility is surprising. HSP2 is located within the genes for
tRNAF and 12S rRNA, and these genes are well-conserved across
mammalian species. Interestingly, the region from −18 to −6 of
HSP2 exhibits substantial interspecies variability (Fig. 2E). The
variable region of the sequence encodes the TψC stem loop of
tRNAF; equivalent structures are predicted for all of the sequences.
We propose that this sequence is responsible for the observed
species specificity. We do not know the selective pressure that has
led to a need to maintain stringent factor–promoter specificity, but
this factor–promoter specificity extends to LSP andHSP1 (10). The
POLRMT-related bacteriophage T7 RNA polymerase uses an
aminoterminal domain to recognize sequences from −17 to −12 of
its promoter (27). It is tempting to speculate that within −18 to −8
of HSP2 is a region recognized by POLRMT and/or TFB2M.
The most unexpected and exciting finding of this study is the
observation that TFAM is not only a transcriptional activator but
also a transcriptional repressor at concentrations that activate
other promoters. This inhibitory activity is manifested on HSP2
(Figs. 1–4). The residues of TFAM known to be uniquely re-
quired for transcriptional activation, particularly the CTD, are
all required for repression (Fig. 3B and Fig. S4A). We interpret
this observation to mean that the two activities are not separable.
You cannot have activation of LSP and/or HSP1 without re-
pression of HSP2, at least in vitro.
Footprinting experiments performed in the past by us and
others on LSP have shown that POLRMT-TFB2M protects from
−18 to+10 of this promoter (10, 14). There is no reason to believe
that the conformation used by POLRMT-TFB2M for initiation
from HSP2 would be different. Therefore, the binding sites for
TFAM at −10, +1, and perhaps even +5 of HSP2 suggested by
our footprinting experiments should interfere with POLRMT-
TFB2M binding (Fig. 3D). Consistent with this model, a 40-fold
excess of POLRMT-TFB2M relative to TFAM precludes in-
hibition, but a fourfold excess does not (Fig. 3E).
Recently, several laboratories have joined forces to study the
human mitochondrial transcriptome in a variety of cell lines (28).
As a part of that study, an in vivo DNase I footprinting experi-
ment was performed with essentially single-nucleotide resolution
(28). That study revealed strong sites of protection in HSP2 and
adjoining sequences (Fig. S8) (28). All of those sites observed by
us in vitro (Fig. 3D) were observed in vivo (Fig. S8). Whether or
not TFAM binding protects these sites in vivo is not known but
could be determined using ChIP-seq methodologies. In addition,
the relevance of the protected sites to gene expression is not
known but will not be straightforward to address experimentally
given the absence of a reverse genetics system for mtDNA.
This study reinforces and clarifies the work of others that has
pointed to the CTD of TFAM as a critical domain for transcrip-
tional functions (5, 8, 20). Deletion of the terminal 10-aa residues
from TFAM supports transcriptional repression (Fig. S4) and
activation (Fig. S5). However, deleting an additional 16-aa resi-
dues eliminates both transcriptional repression (Fig. 3B) and ac-
tivation (Fig. S5B andC). These last 10-aa residues of TFAMvary
from one species to another, but the preceding 16-aa residues do
not (Fig. 4A). Because mouse and bovine TFAM repress tran-
scription from HSP2 (Fig. 4B) and activate transcription from
LSP (Fig. S5 B and C), we conclude that residues 220–236 of
TFAM are those residues most essential to CTD function.
Two groups independently solved the structures for TFAM
complexed with the TRE from LSP (6, 7). Residues 232–236 in-
teract withDNA (Fig. 5A). The conformation of this portion of the
CTD is likely stabilized by the salt bridges between Arg-227, Glu-
148, and Asp-229 (Fig. 5B). In addition, residues 225–229 of one
moleculemay pack against the same residues on a secondmolecule
in a TFAM dimer (Fig. 5B) (7). Residues of the helix between the
two HMG boxes also contribute to interaction between the two
TFAM-DNA complexes. All of these residues are conserved (Fig.
4A). Therefore, these interactions lend a nice structural explana-
tion for the requirement of the CTD of TFAM for its transcrip-
tional functions. Analytical ultracentrifugation experiments
detailed in the work by Wong et al. (20) revealed a monomer–
Fig. 4. Repression of HSP2 transcription by TFAM orthologs in vitro. (A)
Alignment of carboxyl-terminal sequences of TFAMs from human, mouse,
and bovine species. (B) TFAMs from mouse and bovine inhibit runoff tran-
scription from the HSP2-1 template by POLRMT-TFB2M. (C) EMSA of HSP2-1
template over a range of mouse and bovine TFAM concentrations shows
formation of four complexes (I–IV), with complex I present from 0.5 nM as
observed for human TFAM in Fig. 3C.
Fig. 5. Interactions of the TFAM CTD. Structural models were produced
using Protein Data Bank ID code 3TQ6 (7). (A) TFAM residues 232–236
(green) interact with the phosphodiester backbone of bound DNA (red). (B)
Two TFAM-DNA complexes are present in the asymmetric unit and desig-
nated here as chains A (dark green) and B (light green). Structural integrity
of the CTD of each monomer benefits from interaction of Arg-227 in each
monomer with both Asp-229 and Glu-148 of the same monomer. The CTD of
one monomer packs against the CTD of a second monomer, perhaps creat-
ing a mechanism for association between TFAM-DNA complexes.



























dimer equilibrium for TFAM that was lost when the CTD was
deleted. The interface suggested here may be responsible for
TFAM dimerization. Interactions between TFAM monomers
bound at different positions of HSP2 could contribute further to
the efficiency with which TFAM represses this promoter.
Our data would suggest that the presence of any TFAM
should lead to repression of HSP2. If this repression were the
case, then mRNAs would never be produced. Clearly, all mito-
chondria contain TFAM, although nucleoids vary in their TFAM
levels in vivo (29). TFAM is a substrate for degradation by the
mitochondrial Lon protease and perhaps contributes to TFAM
depletion (30). For this mechanism to work in vivo, a mechanism
may be needed to specifically control the functions of TFAM
in transcription without altering protein levels globally. Post-
translational modification of the CTD could serve such a func-
tion. One report of TFAM acetylation exists, although this study
did not map the site of this modification (31). It is also now clear
the cytosines of human mtDNA are both methylated and
hydroxymethylated (32). Epigenetic marks such as these marks
could also influence the sites to which TFAM binds and the
ensuing transcriptional response.
In going from a disabled CTD or low TFAM level to a fully
enabled CTD or a high TFAM level, the transcriptional program
would go from HSP2 > HSP1 >>> LSP to LSP >> HSP1 >>
HSP2 followed by HSP1 >>> LSP1 >>>HSP2. HSP2 is required
for maintenance of the electron transport chain. LSP and HSP1
are required for mitochondrial biogenesis. LSP produces the
primer for replication of the heavy strand (3). Full activation of
HSP1 will produce an abundance of 12S and 16S rRNAs, likely to
double the mass of ribosomes before fission. Such a dichotomy
makes biological sense, because it would uncouple a transcrip-
tional program supporting mitochondrial homeostasis from one
supporting mitochondrial biogenesis. One caveat to this hypothe-
sis is that LSP-driven expression of ND6 protein and tRNAs
would need to be stable enough to not require transcription of
these genes when HSP2 is the primary promoter operating. This
hypothesis also assumes termination of transcription after com-
pletion of 16S rRNA when initiated from HSP1 (12). This
mechanism would predict that each promoter would be affected
differently in experiments in which TFAM levels are increased or
decreased. Unfortunately, none of the studies performed to date
that modulate the intracellular TFAM level have evaluated
transcripts from all three promoters (33, 34).
The past few years have witnessed a revival in molecular studies
of human mitochondrial transcription because of the creation of
more robust in vitro systems (11, 14). The TFAM-regulated, two-
component system documented recently may be even more com-
plex than previously imagined (4). The response of each promoter
to TFAM is unique. Here, we have shown that TFAM is no longer
only a transcriptional activator but also a transcriptional repressor.
It will be important to determine if the promoter-specific, TFAM-
dependent regulation observed in vitro also occurs in cells.
Materials and Methods
Materials. Recombinant proteins and substrates were produced as described
previously (14). All other regents were of the highest grade available. A
complete description of materials and corresponding sources is given in SI
Materials and Methods.
Assays. In vitro transcription assays (14), DNase I footprinting (14), and EMSA
(19) were performed as described previously. Detailed protocols are pro-
vided in SI Materials and Methods.
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